Loading stock data…
BioCryst Pharmaceuticals (BCRX)
$9.34-0.04 (-0.43%)
Market ClosedLast close Jul 24
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioCryst Pharmaceuticals, Inc. in the Healthcare sector is trading at $9.34 with a market capitalization of $2.3B. Wall Street consensus targets $21.00 (11 analysts), implying a +124.8% move over the next 12 months. The stock is currently 17% below its 52-week high of $11.22, remaining 14.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +124.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $156.41M↓ | $406.56M↑ | $159.40M↓ | $163.35M↑ | $145.53M |
| Gross Profit | $151.04M↓ | $397.03M↑ | $157.21M↓ | $160.56M↑ | $140.97M |
| Operating Income | -$701.60M↓ | $260.38M↑ | $29.59M↓ | $29.79M↑ | $21.23M |
| Net Income | -$721.81M↓ | $245.84M↑ | $12.90M↑ | $5.08M↑ | $32,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
82.69%
Volume
Today's trading volume
1.85M
Recent News
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers
BioCryst Pharmaceuticals stock has delivered a 54.7% return over the past three years, and the latest valuation checks still suggest the shares lean cheap rather than stretched. A 54.7% three year return puts BioCryst in clear recovery territory, which raises the question of how much of the story is already reflected in the price. The shift toward external innovation and partnerships can support expectations for a focused rare disease pipeline, while closing the Birmingham facility and...
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?
Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.
BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility
BioCryst Pharmaceuticals (NasdaqGS:BCRX) is ending its internal discovery programs and closing its Birmingham, Alabama facility. The company plans to pivot toward external innovation in rare diseases, focusing on partnered or acquired assets. This corporate shift follows renewed M&A discussion in biotech after a large sector acquisition. BioCryst Pharmaceuticals is best known for treatments targeting rare diseases, an area that continues to attract interest from larger drug companies and...
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.